CASP8 and breast cancer: In addition, CASP8 seems to be more strongly associated with less favourable markers, although it is not significantly different in a case-only design comparing unfavourable against favourable markers (i.e., BC cases with ER-negative, lymph node-positive or high-grade tumours compared to women with ER-positive, lymph node-negative and low-grade tumours).